The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback